Active — Not RecruitingNot Applicable

Neuromodulation of Mind-Wandering in Depression

United States80 participantsStarted 2023-03-20

Plain-language summary

The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that DOWN-modulation of the posterior cingulate cortex (PCC), a key DMN node, will decrease DMN resting state functional connectivity, perfusion, and activation during a cognitive-affective task (description below). The investigators also hypothesize that DOWN-modulation of the PCC will be associated with decreased mind-wandering and increased mindfulness. Finally, the investigators hypothesize that the opposite will be true for UP-modulation of the PCC.

Who can participate

Age range18 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female
✓. Age 18-64
✓. Right-handed
✓. Normal or corrected-to normal vision and hearing
✓. For group with depression, current diagnosis of depression

Exclusion criteria

✕. Active significant medical illness or neurological disorder
✕. MRI scan contraindications (e.g., metal implant, claustrophobia, weigh over 250 pounds, etc.)
✕. For healthy control group, any current or past history of psychiatric disorders

What they're measuring

Negative self-judgment frequency during task

Timeframe: 3 hours

Default mode network activation during task

Timeframe: 3 hours

Rumination

Timeframe: 1 week

Trial details

NCT IDNCT04832685

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Depression trials